drugset

drugset / Trial / NCT03070301

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

NCT03070301 ↗

Phase 2 Completed 21 enrolled Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute · collab M.D. Anderson Cancer Center · collab Novartis · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.

Timeline

Start: 2017-02-27
Primary completion: 2024-01-31
Completion: 2024-01-31

Publications

Raj N, Zheng Y, Hauser H, Chou J, Rafailov J, Bou-Ayache J, Sawan P, Chaft J, Chan J, Perez K, Rudin C, Tang L, Reidy-Lagunes D. Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors. Endocr Relat Cancer. 2021 Apr;28(4):237-246. doi: 10.1530/ERC-20-0446.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Everolimus	Small molecule	2.5 mg	—
Subject	Everolimus	Small molecule	5 mg	—
Subject	Ribociclib	Small molecule	200 mg	—
Subject	Ribociclib	Small molecule	300 mg	—

Indications